Related Experiment Video
Updated: Oct 11, 2025

Porcine Corneal Tissue Explant to Study the Efficacy of Herpes Simplex Virus-1 Antivirals
Published on: September 20, 2021
Efficacy of Systemic Acyclovir as Adjuvant Therapy for Oral Lichen Planus
Dewi Zakiawati1,2, Muhammad Al Farisyi1, Tenny Setiani Dewi2
1Oral Medicine Specialist Degree Program, Faculty of Dentistry, Universitas Padjadjaran, Bandung, Indonesia.
Abstract:
BACKGROUND Oral lichen planus (OLP) is a chronic inflammatory disease involving the oral mucosa, associated with the T-cell activity that mediates an autoimmune condition, with various predisposing factors, such as herpes simplex virus (HSV). The first-line treatment is topical corticosteroids. However, additional therapy can be given according to the underlying factors. This report assessed the efficacy of oral acyclovir as adjuvant therapy in the management of OLP. CASE REPORT A 73-year-old man came to our unit reporting he had recurring sores on the tongue for the past 10 years. The tongue was painful and there was taste impairment. Intraoral examination showed erosion and erythematous areas surrounded by white net-like plaques on the tongue and buccal mucosa, as well as depapillation on 2/3 dorsal anterior of the tongue. The diagnosis of reticular and erosive OLP was determined based on clinical features. The patient was prescribed topical corticosteroids, multivitamins, and mouthwash containing chlorine dioxide. Supporting examinations were performed to rule out systemic predisposing factors. The patient was referred for anti-HSV-1 IgG testing, and it was reactive (34.8 U/mL). Thus, oral acyclovir was prescribed. After 2 weeks of antiviral treatment, the tongue pain and altered taste were resolved, and the clinical features showed significant improvement. CONCLUSIONS Management of OLP requires a comprehensive approach. OLP symptoms can be relieved if treatment is not only limited to reducing the inflammation but also seeks to remedy other comorbidities, in this case, administration of an antiviral agent to resolve the HSV-1 involvement.
More Related Videos
06:02Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination
Published on: February 23, 2024
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Tonsillitis II: Management
Antimicrobial Effectiveness
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...